medwireNews

A Japanese real-world study has found higher rates of pneumonitis with first-line pembrolizumab plus chemotherapy among patients with advanced nonsquamous non-small-cell lung cancer than previously reported in clinical trials.

Patients with axial spondyloarthritis who continue treatment with ixekizumab are less likely to experience flares than those who discontinue the IL-17A inhibitor, trial results suggest.

Click through for more details

The BERENICE investigators report a low incidence of cardiac events with the use of pertuzumab–trastuzumab-based neoadjuvant and adjuvant regimens in patients with HER2-positive, early breast cancer after 5 years of follow-up.

Findings from two Norwegian trials published in JAMA do not support routine therapeutic drug monitoring with biologics or dose reduction of conventional DMARDs in patients with inflammatory diseases.

Paired analysis of primary and relapsed breast cancer specimens shows that many HER2-negative patients switch between HER2-low and HER2-0 expression during disease progression.